全文获取类型
收费全文 | 919篇 |
免费 | 0篇 |
国内免费 | 1篇 |
专业分类
综合类 | 2篇 |
化学工业 | 10篇 |
金属工艺 | 1篇 |
机械仪表 | 1篇 |
建筑科学 | 2篇 |
轻工业 | 14篇 |
无线电 | 7篇 |
一般工业技术 | 18篇 |
冶金工业 | 863篇 |
自动化技术 | 2篇 |
出版年
2019年 | 1篇 |
2016年 | 1篇 |
2014年 | 1篇 |
2013年 | 5篇 |
2012年 | 1篇 |
2010年 | 1篇 |
2009年 | 1篇 |
2008年 | 4篇 |
2007年 | 4篇 |
2006年 | 1篇 |
2005年 | 1篇 |
2004年 | 2篇 |
2002年 | 6篇 |
2001年 | 4篇 |
2000年 | 1篇 |
1999年 | 24篇 |
1998年 | 247篇 |
1997年 | 162篇 |
1996年 | 92篇 |
1995年 | 48篇 |
1994年 | 51篇 |
1993年 | 55篇 |
1992年 | 7篇 |
1991年 | 14篇 |
1990年 | 11篇 |
1989年 | 7篇 |
1988年 | 9篇 |
1987年 | 19篇 |
1986年 | 8篇 |
1985年 | 6篇 |
1983年 | 1篇 |
1982年 | 5篇 |
1981年 | 5篇 |
1980年 | 9篇 |
1978年 | 3篇 |
1977年 | 25篇 |
1976年 | 75篇 |
1965年 | 1篇 |
1964年 | 1篇 |
1955年 | 1篇 |
排序方式: 共有920条查询结果,搜索用时 31 毫秒
1.
2.
An endocrine testing center (ETC) is a universal requirement for the practice of endocrinology. Modifications of the Mayo Clinic model for an ETC should be applicable to most endocrine practices. Key components of an ETC include a centralized testing area, registered nurse-physician team, detailed testing protocols, and patient education programs. 相似文献
3.
4.
AB Deisseroth Z Zu D Claxton EG Hanania S Fu D Ellerson L Goldberg M Thomas K Janicek WF Anderson 《Canadian Metallurgical Quarterly》1994,83(10):3068-3076
Relapse after autologous bone marrow transplantation for chronic myelogenous leukemia (CML) can be due either to the persistence of leukemia cells in systemic tissues following preparative therapy, or due to the persistence of leukemia cells in the autologous marrow used to restore marrow function after intensive therapy. To help distinguish between these two possible causes of relapse, we used safety-modified retroviruses, which contain the bacterial resistance gene NEO, to mark autologous marrow cells that had been collected from patients early in the phase of hematopoietic recovery after in vivo chemotherapy. The cells were then subjected to ex vivo CD34 selection following collection and 30% of the bone marrow were exposed to a safety-modified virus. This marrow was infused after delivery of systemic therapy, which consisted of total body irradiation (1,020 cGy), cyclophosphamide (120 mg/kg), and VP-16 (750 mg/m2). RT PCR assays specific for the bacterial NEO mRNA, which was coded for by the virus, and the bcr-abl mRNA showed that in two evaluable CML patients transplanted with marked cells, sufficient numbers of leukemia cells remained in the infused marrow to contribute to systemic relapse. In addition, both normal and leukemic cells positive for the retroviral transgenome persisted in the systemic circulation of the patients for at least 280 days posttransplant showing that the infused marrow was responsible for the return of hematopoiesis following the preparative therapy. This observation shows that it is possible to use a replication-incompetent safety-modified retrovirus in order to introduce DNA sequences into the hematopoietic cells of patients undergoing autologous bone marrow transplantation. Moreover, this data suggested that additional fractionation procedures will be necessary to reduce the probability of relapse after bone marrow transplantation in at least the advanced stages of the disease in CML patients undergoing autologous bone marrow transplantation procedures. 相似文献
5.
K Stubbs LA Martin DC Dimmitt N Pready WF Hahne 《Canadian Metallurgical Quarterly》1997,37(10):926-936
In previous studies, dolasetron was shown to have both renal and hepatic elimination mechanisms. This study was conducted to determine the impact of varying degrees of hepatic dysfunction on the pharmacokinetics and safety of dolasetron and its reduced metabolites. Seventeen adults were studied: six healthy volunteers (group I), seven patients with mild hepatic impairment (Child-Pugh class A; group II), and four patients with moderate to severe hepatic impairment (Child-Pugh class B or C1; group III). Single 150-mg doses of dolasetron mesylate were administered intravenously and orally, with a 7-day washout period separating treatments. After intravenous administration, no differences were observed between healthy volunteers and patients with hepatic impairment in maximum plasma concentration (Cmax), areas under the plasma concentration-time curve (AUC), or elimination half-life (t1/2) of intact dolasetron. No significant differences were found in Cmax, AUC, or apparent clearance (C(lapp)) of hydrodolasetron, the primary metabolite of dolasetron. The mean t1/2 increased from 6.87 hours in group I to 11.69 hours in group III. After oral administration, C(lapp) of hydrodolasetron decreased by 42%, and Cmax increased by 18% in patients with moderate to severe hepatic impairment. There were less changes in patients with mildly hepatic impairment. Total percentage of dose excreted as metabolites was similar for healthy volunteers and patients with hepatic impairment, although urinary metabolite profiles differed slightly. Dolasetron was well tolerated and there were no apparent differences in adverse effects between groups or treatments. Because hepatic impairment did not influence Cl(app) of hydrodolasetron after intravenous administration, and the range of plasma concentrations of hydrodolasetron after oral administration was not different from those observed in healthy volunteers, dosage adjustments are not recommended for patients with hepatic disease and normal renal function. 相似文献
6.
There are several tumors and tumorlike entities of bone that do not easily fit into the specific classifications provided elsewhere in this issue. In this article, several seemingly unrelated entities are discussed, including cystic diseases of bone (simple bone cysts and aneurysmal bone cysts), Langerhans' cell histiocytosis, benign and malignant vascular tumors of bone, and adamantinoma of long bone and its relationship to osteofibrous dysplasia. 相似文献
7.
Abe Schwartz Lili Wang Edward Early Adolfas Gaigalas Yu-zhong Zhang Gerald E. Marti Robert F. Vogt 《Journal of research of the National Institute of Standards and Technology》2002,107(1):83-91
The quantitation of fluorescence radiance may at first suggest the need to obtain the number of fluorophore that are responsible for the measured fluorescence radiance. This goal is beset by many difficulties since the fluorescence radiance depends on three parameters 1) the probability of absorbing a photon (molar extinction), 2) the number of fluorophores, and 3) the probability of radiative decay of the excited state (quantum yield). If we use the same fluorophore in the reference solution and the analyte then, to a good approximation, the molar extinction drops out from the comparison of fluorescence radiance and we are left with the comparison of fluorescence yield which is defined as the product of fluorophore concentration and the molecular quantum yield. The equality of fluorescence yields from two solutions leads to the notion of equivalent number of fluorophores in the two solutions that is the basis for assignment of MESF (Molecules of Equivalent Soluble Fluorophore) values. We discuss how MESF values are assigned to labeled microbeads and by extension to labeled antibodies, and how these assignments can lead to the estimate of the number of bound antibodies in flow cytometer measurements. 相似文献
8.
9.
10.